Release Date: 23-Jan-2025
Lutikizumab (ABT-981) is a dual-variable-domain interleukin (IL) 1andalpha;/1andbeta; antagonist developed by AbbVie, designed to target and neutralize two key inflammatory cytokines: IL-1andalpha; and IL-1andbeta;. These cytokines play a crucial role in immune regulation and inflammatory processes, and their overexpression has been linked to a variety of immune-mediated diseases. Lutikizumab uses a proprietary technology called Dual Variable Domain Immunoglobulin (DVD-Igandtrade;), which combines the functionality and specificity of two monoclonal antibodies into a single molecule. This unique design allows it to simultaneously bind to and inhibit both IL-1andalpha; and IL-1andbeta;, potentially offering a more efficient therapeutic approach compared to traditional monoclonal antibodies.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The therapeutic potential of lutikizumab lies in its ability to modulate the inflammatory response driven by IL-1andalpha; and IL-1andbeta;. In diseases such as hidradenitis suppurativa (HS) and ulcerative colitis, IL-1andalpha; and IL-1andbeta; are often elevated, contributing to inflammation, pain, and tissue destruction. By neutralizing these cytokines, lutikizumab aims to reduce inflammation, alleviate pain, and slow the progression of tissue damage. In particular, studies have shown elevated levels of IL-1andalpha; and IL-1andbeta; in HS lesions, suggesting that inhibiting these cytokines may provide therapeutic benefits in this chronic skin condition.
Lutikizumab is being investigated in several immune-mediated diseases, with Phase 3 clinical trials underway for HS and Phase 2 trials ongoing for ulcerative colitis. The drug has shown promise in early studies, where it demonstrated anti-inflammatory activity and similar behavior to conventional monoclonal antibodies following both single and multiple doses. If successful in these trials, lutikizumab could become a valuable treatment option for patients with conditions driven by excessive IL-1andalpha;/1andbeta; activity. Its dual-targeting mechanism positions it as a potentially powerful tool in managing inflammatory diseases.